naa a22 4500 510764274 CHVBK 20180411083151.0 cr unu---uuuuu 180411e20130501xx s 000 0 eng 10.1007/s12094-012-0964-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0964-2 An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents [Elektronische Daten] [M. Majem, C. Pallarès] Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. Although erlotinib is the only recommended third-line therapy, several drugs are being used in the clinic. Recent studies have focused on combining targeted agents with approved therapies, including broad-spectrum multikinase inhibitors targeting multiple ErbB Family receptors and multitargeted anti-angiogenic agents targeting the vascular endothelial growth factor receptor, platelet-derived growth factor receptor and fibroblast growth factor receptor pathways. Here, we review targeted therapies that are being evaluated in second- and third-line settings in NSCLC, including the ErbB Family Blocker afatinib (BIBW 2992), multityrosine kinase inhibitors (pelitinib [EKB-56]), neratinib [HKI-272], canertinib [CI-1033], lapatinib [GW-572016], dacomitinib [PF-299804]) and multitargeted anti-angiogenic agents (vandetanib [ZD6474], sunitinib [SU11248], sorafenib [BAY43-9006], nintedanib [BIBF1120], axitinib [AG-013736], cediranib [AZD2171], motesanib [AMG 706], linifanib [ABT869] and pazopanib [GW786034]). Federación de Sociedades Españolas de Oncología (FESEO), 2012 NSCLC nationallicence Pretreated patients nationallicence ErbB Family Blocker nationallicence Multityrosine kinase inhibitors nationallicence Anti-angiogenic agents nationallicence Majem M. Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025, Barcelona, Spain aut Pallarès C. Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025, Barcelona, Spain aut Clinical and Translational Oncology Springer Milan 15/5(2013-05-01), 343-357 1699-048X 15:5<343 2013 15 12094 https://doi.org/10.1007/s12094-012-0964-2 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0964-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Majem M. Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025, Barcelona, Spain aut NATIONALLICENCE 700 1- Pallarès C. Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025, Barcelona, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/5(2013-05-01), 343-357 1699-048X 15:5<343 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer